Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 for Chemoprevention of Colorectal Cancer
NCT05630794Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2025
- Primary completion
- Jul 2028
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dordaviprone in colorectal cancer (CRC), sponsored by National Cancer Institute. Primary endpoint: Proportion of participants with unacceptable toxicity. Started Oct 2025; status: recruiting.
02
Drugs
dordaviprone
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05630794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630794.